Within the multiform liver/kidney microsomal (LKM) family, a subgroup of sera that reacts with a liver cytosolic (LC) protein has been isolated and the new antigen-antibody system is called LC1.
Abstract
Within the multiform liver/kidney microsomal (LKM) family, a subgroup of sera that reacts with a liver cytosolic (LC) protein has been isolated and the new antigen-antibody system is called LC1. Unlike LKM antibody type 1 (anti-LKM1), anti-LC1 is said to be unrelated to hepatitis C virus (HCV) infection and has therefore been proposed as a marker of 'true' autoimmune hepatitis type 2. Altogether 100 LKM1 positive sera were tested by immunodiffusion (ID). Twenty five gave a precipitation line with human liver cytosol; 17 of the 25 also reacted with rat liver cytosol. Thirteen of the 25 sera were anti-HCV positive by second generation ELISA: anti-HCV positive patients were significantly older (p<0.001) and tended to have less active disease. No difference in anti-LCl titre or ID immunoreactivity was found between anti-LC1/anti-HCV positive and anti-LCl/anti-HCV negative cases. In Western blotting experiments, 14 of 24 ID positive sera recognised a 58 kD protein of the human cytosolic fraction and 11 gave a similar reactivity when tested with human microsomes, suggesting the presence of the LC1 target antigen also in the microsomal preparation. Western blotting reactivity was similar for both anti-HCV positive and negative sera. These data confirm the existence of the LC1 antigen-antibody system that partially overlaps with LKM1, and that it is an additional marker of juvenile autoimmune hepatitis type 2. It does not, however, discriminate between patients with and without HCV infection. (Gut 1995; 36: In 1990-91 we showed that most Italian adults with anti-LKMI positive chronic hepatitis are positive both for antibodies to the newly discovered hepatitis C virus (HCV)2 3 and for serum HCV RNA.4 These data were confirmed by Lunel et al,5 who added the important observation that, unlike the adult disease, the childhood-juvenile form of anti-LKM1 positive chronic hepatitis is remarkably free from HCV infection. As a consequence, the diagnosis of type 2 autoimmune hepatitis has mainly been confined to a rare chronic active liver disease of unknown aetiology, characterised by female predominance, young age at onset, and a frequent association with autoimmune disorders of other organs (endocrine pancreas, thyroid, skin). Both the biochemical and histological activity of type 2 autoimmune hepatitis are said to be high; untreated the disease runs a severe course, with a high rate of progression to liver cirrhosis.'
The clinical, biochemical, and histological picture closely resembles that of the classic autoimmune chronic active hepatitis seen in young women (so called 'lupoid' hepatitis), the differential peculiarity being that type 2 autoimmune hepatitis has a different autoantibody profile (anti-LKM1, instead of antinuclear or anti-actin antibodies, or both, which mark the classic type 1 autoimmune hepatitis).
In 1988 a second autoantibody marker of type 2 autoimmune hepatitis was recognised. This antibody, associated with anti-LKMI in two thirds of positive cases, was found to react with an unidentified protein of liver cytosol and was therefore called anti-liver cytosol 1 (anti-LC1).6 Unlike anti-LKMI, anti-LC1 antibodies were never found in association with HCV infection and were therefore considered a more specific marker of type 2 autoimmune hepatitis than anti-LKM1.7
The present study assessed the relevance of anti-LKM1 and anti-LC 1 in identifying type 2 autoimmune hepatitis in a retrospective series of 100 adults and children with anti-LKM1 positive chronic hepatitis. In Twenty five sera from patients with type 1 autoimmune hepatitis (positive for anti-actin or anti-nuclear antibodies, or both), 25 sera from patients with primary biliary cirrhosis, 20 sera from patients with autoantibody-negative chronic hepatitis C, and 25 sera from healthy blood donor were used as controls.
IMMUNODIFFUSION
Immunodiffusion was performed according to Martini et al.6 Liver cytosol and microsomes were prepared from the surgical specimens of a group 0 adult patient, HBsAg and anti-HCV negative, who had undergone partial hepatectomy for secondary liver deposits, and from male Sprague Dawley rats. Liver was homogenised with a Potter homogeniser in 0.25 M sucrose Tris HC1, 2 mM, pH 7-4 at a dilution of 1:10 (w/v). After two hours of 105000 g ultracentrifugation, the supernatant was collected, dialysed overnight against PBS, and concentrated by centrifugation in an Amicon tube to a protein concentration of 20 mg/ml. Pellets containing microsomal membranes were washed three times and resuspended in PBS at the same protein concentration. The purity of the cytosolic fraction was controlled by electron microscopy. In particular, as previously described,10 no membranous structures were found in the cytosol by negative staining.
All sera were screened undiluted with human liver cytosol and the titres of those found positive were assessed by doubling the dilution to end point. Sera positive with human cytosol by ID were tested with rat cytosol and human and rat microsomes.
The immunological specificity of the reaction obtained by ID in our system was controlled by obtaining an identity reaction with a reference anti-LC 1 positive serum, kindly provided by Professor J C Homberg (Paris).
IMMUNOFLUORESCENCE AND ABSORPTION EXPERIMENTS
Indirect immunofluorescence (IFL) was performed according to standard procedures on 5 ,um cryostat sections of rat liver and kidney with serum diluted 1:40 with PBS. The IFL pattern in each case was re-evaluated on the basis of the fluorescence observed on rat liver sections and scored as anti-LKM1 when the fluorescence was uniform throughout the liver lobule, or as anti-LC 1 when the cytoplasmic staining spared two to three Figure  1 ). (Fig 2 panels (A) and (B) ). When these 10 sera were tested by ID with either rat or human microsomes, all but the one giving no renal staining by IFL were reactive with at least one of the two microsomal preparations.
In the 15 cases deemed anti-LKM1 by IFL and giving a precipitation line with the human cytosol by ID, the absorption with either liver or kidney microsomes abolished the anti-LKM1 reactivity from both liver and kidney sections, disclosing a previously masked anti-LC 1 pattern on the liver substrate. Accordingly, the renal staining of the nine sera scored as anti-LC1 on the liver sections disappeared after absorption with both liver and kidney microsomes, leaving unmodified the anti-LC 1 pattern on rat liver.
IMMUNOBLOTlING
The monoclonal antibody BI-114/2 reacted with a 50 kD microsomal protein, corresponding to CYP2D6, but not with any of the cytosolic proteins.
Immunoblotting reactivity of 25 anti-LC1 positive sera is reported in Table I . Fourteen of the 24 sera tested (58%) reacted with a human cytosolic protein of 58 kD (Fig 3) and 11 of them showed a similar reactivity against human microsomes. The 58 kD band was significantly associated with higher ID titres (p<0001 Wilcoxon rank sum test). Other reactivities at 39, 50, and 66 kD were observed with human microsomes in 4 (17%), 11 (46%), and 6 (25%) sera, respectively (Fig 4) .
No IB reaction with the 58 kD cytosolic protein was observed with 45 LKM1 positive/anti-LC1 negative sera and with the control group sera.
Antibodies eluted from the 58 kD protein of the liver cytosol reacted with a protein of the same molecular weight present both in human cytosol and human microsomes, as shown in Figure 5 . Table II The age distribution of the patients positive for both anti-LC1 and anti-LKM1 antibodies shows that the anti-LC 1 antibody is never associated with anti-HCV reactivity in the paediatric patients. In contrast 13 of the 20 adults studied were positive for both anti-LC 1 and anti-HCV (Fig 6) .
Discussion
This study confirms that the LC 1 antigen-antibody system is closely associated with LKM1 positive chronic hepatitis. Anti-LCl1 detection is frequently missed in the routine IFL test since its specific immunomorphological pattern is masked by the coexistence of anti-LKM1 antibody in the same serum. The specific anti-LC 1 pattern can probably be recognised only when the anti-LC 1 titre is higher than that of anti-LKIM1. Careful evaluation of the IFL pattern on rat liver disclosed the typical anti-LC1 pattern in 10 of the 25 sera positive by ID for anti-LC 1 and previously classified as anti-LK.M 1. The coexistence of anti-LKM 1 in nine of these 10 sera, however, is suggested by at least three lines of evidence. The first is that the IFL positivity of renal tubules was, on consecutive sections, superimposable on that of anti-LKM 1, and was specifically removed by absorption with both kidney and liver microsomal fractions. Secondly, the nine sera gave a positive immunoprecipitation line with rat or human liver microsomes, or both. Thirdly, several IB reactivities with human microsomes, typically associated with LKM1, were found in four of these nine sera (two at 50 kD and two at 66 kD).
Immunoprecipitation therefore remains the test of choice for detecting anti-LC1; human cytosol turned out to be more sensitive than rat cytosol, which reacted only with 680/% of the sera positive with the human substrate.
High titre anti-LC1 positive sera recognised a unique cytosolic polypeptide of 58 kD; a cross reactive protein of the same molecular weight was present in the microsomal preparation, as shown by the elution experiments. The 58 kD reactivity detected in this study presumably corresponds to the 62 kD band reported by Abuaf et al. 7 This IB reactivity is strictly associated with a positive ID test for anti-LC 1, since it has never been found in the 45 anti-LKM1 positive/anti-LC1 negative sera tested. Whether this 58 kD protein is structurally present in the microsomal membranes or represents cytosolic contamination remains uncertain. Identification of the anti-LC 1 target antigen will clarify its relationship with CYP2D6 and will offer a more specific test for anti-LC 1 detection.
Anti-LC 1 has been proposed as a more specific marker of type 2 autoimmune hepatitis than anti-LKM 1, since its presence was never associated with anti-HCV positivity in the original report. This finding was confirmed only in the paediatric subset of our patients, however, while a substantial proportion of the adults do have markers of HCV infection. For the purposes of type 2 autoimmune hepatitis diagnosis, the specificity of anti-LC 1 is therefore similar to that of anti-LKM1. The overall picture of anti-LKM 1 or anti-LC 1 positive autoimmune hepatitis or both, is that of a childhood-juvenile disease with a peculiar autoantibody spectrum and biochemical and histological changes similar to those of the classic anti-nuclear/anti-actin positive autoimmune hepatitis. The relation between anti-LC 1 and HCV remains uncertain and its importance has still to be established.
